CD19-targeted chimeric antigen receptor (CAR) T cells are currently being tested in the clinic with very promising outcomes. However, limitations to CAR T cell therapy exist. These include lack of efficacy against some tumors, specific targeting of tumor cells without affecting normal tissue and retaining activity within the suppressive tumor microenvironment. Whereas promising clinical trials are in progress, preclinical development is focused on optimizing CAR design, to generate "armored CAR T cells," which are protected from the inhibitory tumor microenvironment. Studies investigating the expression of cytokine transgenes, combination therapy with small molecule inhibitors, or monoclonal antibodies, are aimed at improving the antitumor efficacy of CAR T cell therapy. Other strategies aimed at improving CAR T cell therapy include using dual CARs and chemokine receptors to more specifically target tumor cells. This review will describe the current clinical data and some novel armored CAR T cell approaches for improving antitumor efficacy therapy.
CLINICAL EXPERIENCE WITH CAR T CELL TREATMENT OF B-CELL MALIGNANCIES
Despite the promising antitumor activity of CD19-or CD20targeted CAR modified T cells in animal models, limited clinical response was observed in initial clinical trials with first-generation autologous CAR modified T cells lacking costimulatory signal, leading to limited persistence of the CAR T cells. 1 To overcome the lack of T cell costimulation in the firstgeneration CARs, 2 approaches have been used. Expression of CARs in antigen-specific T cells such as Epstein-Barr virusspecific T cells, 2 and incorporation of costimulatory signaling domains into the CAR (second-generation CAR). By incorporating costimulatory domains such as CD28, CD137 (4-1BB), or CD134 (OX40) to the CARs, several groups demonstrated increased persistence and antitumor efficacy in animal models. [3] [4] [5] [6] Similarly, significantly enhanced expansion and persistence of the second-generation CAR T cells have been demonstrated in humans when CD19-targeted first and second-generation CAR T cells were simultaneously infused in patients with B-cell lymphoma. 7 However, it remains unclear whether any particular costimulatory molecule is superior to another, and the current ongoing clinical trial wherein patients with relapsed chronic lymphocytic leukemia (CLL) are simultaneously infused CD19-tarteted secondgeneration CARs comparing CD28 and 4-1BB costimulation will partly address the question (NCT 00466531).
CD28z CARs in CLL and Indolent B-Cell Lymphoma
The antitumor efficacy of second-generation CAR T cells in patients with B-cell malignancies was first reported in 2010. A patient with advanced follicular lymphoma experienced a partial remission (PR) and long-term B-cell aplasia after infusion of CD19-targeted CD28/CD3ζ CAR. 8 Subsequently, the same group of investigators reported the outcome of 4 patients with relapsed CLL treated with CD19-targeted CD28/CD3ζ CAR T cells. All patients received nonmyeloablative-conditioning therapy consisting of fludarabine and cyclophosphamide before T cell infusion, and one patient achieved complete remission (CR) and 3 patients achieved PR. 9 We have reported the similar encouraging results in 8 patients with purine analog-refractory or relapsed CLL with bulky lymphadenopathy who received the autologous CD19-targeted CD28/CD3ζ CAR T cells. Of the 6 evaluable patients, one patient achieved minimal residual disease-negative CR, 2 patients achieved PR, and 2 patients had stable disease despite rapid tumor progression before therapy. 10, 11 To better assess the efficacy of CAR T cells in minimal disease setting, we are conducting a phase 1 study of CD19-targeted CD28/CD3ζ CAR T cells in patients with previously untreated CLL who have residual disease after frontline chemotherapy (NCT01416974). 12
CD28z CARs in Acute Lymphoblastic Leukemia
Striking activity of the CD28/CD3ζ CAR T cells was observed in patients with relapsed B-cell acute lymphoblastic leukemia (ALL), and first reported in 2013. 13 Five patients with relapsed ALL received CD19-targeted CD28/CD3ζ CAR T cells, and all patients experienced rapid tumor eradication and achieved minimal residual disease-negative CR. Therapy was well tolerated, although significant cytokine release syndrome was observed in patients with large tumor burden at the time of T cell infusion. Updated results from this trial report CRs in 10 of 12 treated patients with chemo-refractory ALL including patients with Philadelphia chromosome-positive ALL. 14 Despite the promising results of CAR T cell therapy in patients with ALL, there remains room for improvement to achieve equivalent results in patients with CLL. Novel preclinical studies aimed at improving this therapy include the use of different cells, combination therapies, and modification of T cells with cytokine transgenes (Fig. 1 ).
CAR EXPRESSED ON DIFFERENT CELL TYPES
To date, clinical application of CAR T cell therapy has used αβ T cells, that is, a T cell expressing a T cell receptor (TCR) consisting of an α and a β chain. However, alternative T cell types have been investigated in preclinical studies. These include γδ T cells, precursor T cells, and T cells differentiated from induced pluripotent stem cells (iPSCs).
CARs γδ T Cells
In γδ T cells, the TCR is composed of γ and δ molecules, which recognize a limited number of antigens in an major histocompatibility complex-unrestricted fashion. 15 These cells have an inherent antitumor activity and lack alloreactivity and have lower potential for causing graft versus host disease, making them ideal for adoptive transfer therapy. Deniger et al 16 modified γδ T cells to express a CD19-targeted CD3ζ/CD28 CAR. The CAR γδ T cells were subsequently expanded on K562 artificial antigen-presenting cells, resulting in a polyclonal population of CAR γδ T cells. Expression of the CAR-mediated lysis of normally γδ T cell-resistant cell lines, including human pre B-ALL Nalm6 tumor cells. The antitumor efficacy of CAR + γδ T cells was tested using a xenogeneic murine model wherein weekly infusions of γδ CAR + T cells led to delayed growth of tumor. It remains to be determined whether γδ T cells provide a superior antitumor efficacy compared to αβ T cells and whether alternate signaling domains may stimulate a more effective antitumor response from these cells.
CAR T Cells From Precursor or Stem Cells
Differentiation of hematopoietic stem cells into committed T-lineage precursor cells resulted in "off the shelf " allogeneic T cells for adoptive cell therapy. Using mouse models, Zakrzewski et al 17 demonstrate that transfer of major histocompatibility complexdisparate T cell precursors into irradiated recipients resulted in some antitumor efficacy. Retroviral transduction resulted in expression of a CD19-targeted first-generation CAR and was shown to increase the antitumor efficacy of these cells. Importantly, these T cell precursors develop into mature T cells in the recipient and were recipient-tolerant, as no evidence of graft versus host disease was observed. In another attempt to generate a large population of tumor-targeted T cells, Themeli et al 18 used iPSCs to generate human T cells (T-iPSCs-T) that are phenotypically defined, functional, and lentivirally transduced to express a CD19-targeted CD3ζ/CD28 CAR. The T-iPSCS-T cells expressing the CD19targeted CAR, 1928z, secreted IL-2, TNF-α, and IFN-γ and were cytotoxic against human CD19-positive tumors in vitro and in vivo. The T-iPSCs-T cells resembled γδ T cells, functionally and phenotypically, and like CAR γδ T cells, CAR T-iPSCS-T cells induced rapid eradication of human Burkitt lymphoma Raji tumors in a preclinical murine model. Whereas there remains a significant amount of investigation into the phenotype, function, and safety of these cells, these studies provide a proof of principle that stem cells can be differentiated into T cells and targeted to tumor for effective anticancer therapy.
CAR PLUS CYTOKINE/TRANSGENE
Several strategies to improve the antitumor effect of adoptive T cell therapy use expression of a cytokine transgene in CAR T cells. CAR T cells, which provide autocrine growth factors and stimulatory cytokines, is one approach to protect or "armor" the T cells from the suppressive tumor environment. Immune stimulatory cytokines including IL-2, IL-15, and IL-12 have been explored in this context.
IL-2 Transgenes
Interleukin (IL)-2 is an important growth factor for T cells. 19 Early clinical trials demonstrated the importance of IL-2 for effective adoptive T cell transfer therapy. However, the levels of IL-2 required are high and often result in significant toxicity. 20 To overcome this toxicity, Treisman et al 21 investigated an approach whereby tumor-specific T cells were transduced with an IL-2 transgene to provide autocrine IL-2 stimulation. A murine tumorspecific T cell line 14.1 modified to secrete IL-2 was shown to produce high levels of IL-2 and proliferate in the absence of exogenous IL-2. Further to these studies, Liu et al describe the modification of a CD8 T cell clone isolated from tumor infiltrating lymphocytes (TIL) from a metastatic melanoma lesion. When modified to express an IL-2 transgene, this clone was shown to FIGURE 1. Armored CARs for improved antitumor therapy. Numerous strategies exist to improve CAR T cell therapy. These include the following: (1) modification of alternative cell types, for example, γδ T cells or T cells derived from immature precursors; (2) expression of immune stimulatory cytokine transgenes in CAR T cells, for example, IL-2, IL-15, or IL-12: (3) expression of 2 CARs on a single T cell to improve specificity and safety; (4) modified T cell signaling to generate more sustained T cell responses or resistance to immunosuppressive effects, for example, constitutively active AKT or knock-down of Dgk; (5) expression of chemokine receptors to increase T cell survival and trafficking to tumor, for example, transgenic expression of IL-7 Rα or CCR4 on CAR T cells; and (6) combination therapy with monoclonal antibodies (mAb), for example, anti-PD-1 or rituximab, or small-molecule inhibitors, for example, ABT-737 or rapamycin.
proliferate in the absence of exogenous IL-2. 22 A subsequent publication demonstrated that bulk TIL from metastatic melanoma lesions from 2 patients were modified to secrete IL-2. 23 These modified TIL were shown to destroy tumor and proliferate in the absence of exogenous cytokine support and CD4 + T cell help, in response to autologous tumor cells. This group then investigated the clinical application of adoptive transfer of IL-2 secreting TILs. Heemskerk et al 24 treated patients with metastatic melanoma with autologous TIL modified to constitutively produce IL-2. Patients had symptoms of toxicity, and this therapy was not shown to have increased clinical efficacy. Use of an IL-2 transgene has lost favor owing to the toxicity associated with this potent cytokine.
IL-12 Transgene
Several studies have investigated the effects of tumorspecific T cells modified to produce IL-12, a potent immune stimulatory cytokine. Unfortunately, systemic infusion of IL-12 in patients with cancer was found to be highly toxic. 25 However, targeting the IL-12 to the site of the tumor may allow exploitation of its potent effects without systemic toxicity. IL-12 is a heterodimeric protein consisting of a p35 and p40 subunit, which together form active IL-12p70. 26 T cells do not usually secrete IL-12; however, modification of these cells with genes encoding the 2 subunits linked with a flexible hinge region allows the secretion of functional IL-12 by T cells. Ideally, the tumor-targeted T cells traffic to the site of the tumor, where they produce IL-12 within the tumor microenvironment, therefore limiting systemic exposure and potentially reducing toxicity.
Tumor-specific T cells that secrete IL-12 have been tested in several preclinical models. One extensively studied model uses transgenic pmel T cells, where the CD8 + T cells are specific for melanoma antigen, gp100, expressed on B16 tumors. 27 IL-12-producing pmel T cells were shown to have enhanced antitumor function against subcutaneous B16 tumors. 28 These cells had increased accumulation at tumor sites but did not persist in treated mice. This group subsequently reported that pmel T cells constitutively producing IL-12 failed to proliferate, underwent apoptosis, and that higher doses of these cells were toxic to mice. 29 By using the nuclear factor of activated T cells promoter, it was demonstrated that IL-12 secretion could be induced after T cell activation. The authors showed that inducible IL-12 secretion resulted in reduced toxicity while maintaining antitumor efficacy in vivo. This was also confirmed in another study using a CAR specific for vascular endothelial growth factor receptor 2. 30 In a third publication using the pmel model, it was shown that IL-12-secreting T cells "reprogrammed" tumor resident myeloid-derived stromal cells, including myeloid-derived suppressor cells (MDSCs), dendritic cells (DCs), and macrophages. 31 The authors propose that IL-12/pmel T cells allowed MDSCs, DCs, and macrophages to cross-present natural tumor associated antigens and allow transferred cells to infiltrate the tumor and mediate regression. In a fourth study, Kerkar et al 32 demonstrated that IL-12/pmel T cells mediated increased levels of Fas expression on macrophages, DCs, and MDSCs within the tumor microenvironment. IL-12/pmel T cells form a Fas/Fas ligand synapse leading to apoptosis of stromal cells and stromal collapse of subcutaneous B16 tumors. It is unclear how these 2 mechanisms work together for eradication of tumor or which is the more dominant of the two. In addition, these conclusions come with the caveats associated with the pmel model, including the absence of tumor-targeted CD4 + T cells, which may respond to IL-12. These findings in these solid tumor models may be relevant to masses seen in some patients with lymphoma, although more investigation is required.
We used a syngeneic murine model where tumor targeted T cells were infused into immune-competent mice to treat systemic EL4 tumor modified to express human CD19. 33 Mouse T cells were modified to express a CD19-specific first-generation CAR, 19mz, and constitutively secrete IL-12. These T cells had increased cytokine secretion, increased cytotoxic capacity, and completely eradicated tumor in the absence of toxicity. Using murine knockout studies, we demonstrate that antitumor efficacy was dependent on autocrine IL-12 stimulation and subsequent IFN-γ production. Furthermore, CAR/IL-12 T cells were shown to be resistant to regulatory T cell (Treg)mediated suppression, obviating the need for conditioning pretreatment for effective therapy.
It is very clear that IL-12 provides a potent stimulation for tumor-targeted T cells and may subvert the inhibitory microenvironment. The optimal control of IL-12 production (constitutive or inducible) remains to be determined for maximal efficacy and safety. However, given the impressive antitumor effects in multiple tumor models, treatment with IL-12-secreting, tumor-targeted T cells holds much promise for the treatment of cancer.
IL-15
IL-15 is normally produced by monocytes, macrophages, and DCs and stimulates the proliferation and survival of T and natural killer cells. [34] [35] [36] Transgenic expression of this cytokine in tumor-targeted T cells may result in uncontrolled T cell proliferation unless tightly regulated.
Initial studies demonstrated that exogenous IL-15 injections could increase the antitumor efficacy of adoptively transferred pmel T cells. 37 These authors then crossed human IL-15 transgenic mice with pmel mice to generate tumor-targeted T cells that constitutively secreted IL-15. Adoptive transfer of these cells into tumor-bearing mice resulted in enhanced survival.
Following these promising studies, Hsu et al modified T cells to produce IL-15 constitutively. 38 These cells had enhanced proliferation and resistance to apoptosis while maintaining antigen specificity, ideal for adoptive transfer therapy. However, subsequent studies demonstrated that expression of the IL-15 transgene in human T cells could be leukemogenic, as T cells from one donor (of 23 donors) retained proliferative capacity without the addition of exogenous cytokines. 39 These cells stained heterogeneously for CD5 and CD38, inconsistent with T cell leukemia, but they were demonstrated to be clonal. Further studies showing that short-hairpin RNA-mediated knockdown of the IL-15 receptor decreased proliferation of these cells, proving that the IL-15 was responsible for the uncontrolled T cell growth.
Cytokine transgenes can be coexpressed with a suicide gene (e.g., inducible Caspase9), which provides a reliable method of eradicating transferred cells in the case of adverse events. This "safety switch" has encouraged the use of IL-15 in adoptive T cell transfer therapy. Hoyos et al 40 modified human T cells to express a CD19-specific CD3ζ/CD28 CAR, an IL-15 transgene and the iCaspase9 suicide gene. As predicted, these cells produced IL-15 upon stimulation. Murine models revealed that the CAR/IL-15 cells had increased in vivo expansion and better control of Burkitt lymphoma Raji and Daudi tumor growth, although these T cells did not eradicate systemic tumor in treated mice. The iCaspase9 suicide gene effectively eliminated T cells in vitro and in vivo, demonstrating that this approach could be safer owing to the ability to potentially 
IL-21
Combining CAR T cell therapy with cytokine transgenes may present serious concerns as previously discussed. One strategy to avoid this is to culture CAR T cells in the context of stimulatory cytokines ex vivo to provide benefits without the risk of toxicity. Exogenous IL-21 was added to the culture of CD19-targeted CAR T cells upon expansion with K562 artificial antigen-presenting cells to provide "signal 3" to the T cells for full activation. 41 Inclusion of IL-21 resulted in increased T cell yield as well as increased GzmB expression and IFN-γ secretion. In vivo, IL-21-cultured T cells have increased efficacy against Nalm6 tumors in an immune-compromised murine model. It remains to be seen whether an IL-21 transgene will be used to ensure that T cells receive autologous IL-21 stimulation and whether this approach is safe.
DUAL-TARGETED T CELLS
Dual-targeted CAR T cells have been proposed to improve safety and ensure that CAR T cell activation only occurs in contact with tumor antigens. Expression of 2 CARs on a T cell, each with a different specificity, is proposed to increase the specificity and therefore safety of this approach. Despite the following studies describing glioblastoma and prostate cancer models, this approach could be applied to B-cell malignancies. For example, targeting CLL could be achieved with CARs specific for CD5 and CD19.
Hegde et al used a mathematical model to determine the best 2 tumor associated antigens to target T cells to glioblastoma. 42 Based on screening of patient tumor cells, targeting both Her2 and IL-13Rα was reported to result in maximal antitumor efficacy. Furthermore, treatment of tumor-bearing mice with dualspecific T cells was able to offset antigen escape, resulting in disease eradication and long-term survival of treated mice. In similar studies, Duong et al targeted both folate-binding protein and erbB2 with 2 CARs expressed on a single cell. 43 These authors reported an increased response to model tumor (expressing both antigens) compared to model "normal" tissue (expressing either FBP or erbB2 alone).
A more complex strategy involves separating the activation and costimulatory domains on 2 different CARs expressed in one T cell. Wilkie et al 44 used a first-generation CAR-targeted ErbB2 and a Muc-1-targeted CAR with a CD28 signaling domain. Unfortunately, on T cells expressing both CARs, the authors demonstrate that the costimulatory signal delivered by the second CAR was impaired. It was proposed that engagement of the CD28 containing CAR was affected by steric hindrance of the zeta-containing CAR binding to its target. In similar study, Kloss et al used a first-generation CAR targeted to human CD19, 19z1 and a second costimulatory chimeric receptor (CCR) targeted to prostate-specific membrane antigen that contained both 4-1BB-and CD28-signaling domains. 45 T cells were modified to express either CAR or CCR or both (CCR/CAR). Despite effective tumor elimination by CAR/CCR T cells, murine studies demonstrated that CAR/CCR T cells did not need the second antigen and were able to eradicate tumors that were only positive for human CD19. The authors then generated a suboptimal CAR to be expressed alongside the CCR. It was demonstrated that only mice treated with T cells expressing both the suboptimal CAR and CCR survived. T cells expressing CCR and a suboptimal CAR can only respond to cells expressing both tumor antigens but not either target antigen alone. This strategy proves the principle that targeting 2 antigens with separate CARs can make this therapy safer.
One unique strategy to target T cells is to attack the tissues supporting the tumor, or the tumor stroma. Karkarla et al 46 designed a CAR to target cancer-associated fibroblasts. This CAR was specific for fibroblast activation protein alpha (FAP), which is expressed on cancer-associated fibroblasts on more than 90% of epithelial cancers. The authors investigated a dual-targeted therapy where tumor-bearing mice were treated with FAP-CAR T cells and T cells bearing a CAR that was specific for EphA2, an antigen expressed on the lung tumor cells. Treatment with FAP-CAR T cells and EphA2-CAR T cells resulted in tumor control and enhanced the survival of tumor-bearing mice. This report demonstrates the efficacy of targeting both the tumor and its supporting stromal tissue.
CARs WITH MODIFIED SIGNALING
Modifying the T cell signaling pathways also has been proposed for enhancing antitumor efficacy of adoptive T cell therapy. Intrinsic modifications to allow improved proliferation and antitumor function as well as mediate resistance to Tregs have been reported.
Regulatory T cells are often recruited to tumor sites, and these cells may suppress any endogenous T cells and CAR T cell function. 47 Altering T cell signaling to render CAR T cells resistant to Treg mediated suppression has been proposed to improve CAR T cell function. Sun et al 48 demonstrated that expression of a constitutively active serine/threonine kinase, AKT (caAKT), increased T cell proliferation and cytokine production. T cells expressing caAkt retained the ability to proliferate in the presence of Tregs and were resistant to transforming growth factor β-mediated conversion to suppressive T cells. Using T cells expressing a CAR specific for GD2 (neuroblastoma tumor associated antigen) and caAkt, it was shown that this strategy could result in increased response to tumors. Another publication reported the modification of CD28 signaling domain to create CAR T cells that are resistant to Tregs. 49 The lck-binding domain in the CD28 signaling moiety of the CAR was mutated, preventing the secretion of IL-2. The lck-mutated CAR T cell retained IFN-γ-secreting capacity and was cytotoxic to tumor cells in vitro. The mutated CAR T cell was able to eradicate the tumor in the presence of Tregs and resulted in decreased Treg accumulation at the tumor site, compared to mice treated with a wild type CAR. This study shows that CAR T cell-derived IL-2 may allow for the accumulation of Tregs and subsequent suppression of both CAR and endogenous T cells.
Given that CAR T cells require proteins that are essential for TCR signal transduction, relieving negative regulators of TCR signaling may improve CAR T cell function. Diacylglycerol kinase (Dgk) is an enzyme that limits Ras/Erk activation, essential for T cell activation. By using T cells from Dgk knockout (Dgk −/− ) mice, it was found that Dgk −/− CAR T cells have increased levels of Erk activation in response to antigenic stimulation and increased antitumor function in vitro. 50 Adoptive transfer of Dgk −/− CAR T cells into tumor-bearing mice revealed increased antitumor function in vivo. These findings were extended to show that pharmacological inhibition of Dgk augmented the function of human CAR T cells. Another study describing the mutation of a negative regulator-targeted CblB, which increases the threshold for T cell activation by modulating TCR and CD28 signaling. Stromnes et al 51 demonstrated that CblB abrogation can increase the function of tumor-reactive T cells. The authors demonstrate that Cbl-B knockout (cblb −/− ) T cells had increased proliferation and cytokine secretion and that their cytolytic function was unaffected, and they extend this finding by transducing human CD8 + CD28 − T cell clones with small interfering RNA targeting CblB, with similar results. These studies show that targeting negative regulator of TCR signaling can improve CAR T cell mediated antitumor efficacy, although caution is warranted so as not to confer uncontrolled T cell activation.
CAR T CELLS MODIFIED TO EXPRESS CHEMOKINE RECEPTORS/ COSTIMULATORY LIGANDS
Survival, proliferation, and trafficking of CAR T cells can be improved through the expression of chemokine receptors. Endowing CAR T cells with an increased ability to respond to growth factors or traffic to tumors may permit function in the inhibitory tumor microenvironment.
Vera et al 52 modified T cells to express IL-7 receptor alpha chain (IL-7Rα), which restores their responsiveness to IL-7, a cytokine important for T cell homeostasis. Subsequent studies by Perna et al 53 described the further modification of Epstein-Barr virus-specific T cells with both a GD2-specific CAR and IL-7Rα. Transgenic IL-7Rα expression resulted in increased proliferation and resistance to Treg-mediated suppression in vitro and in vivo. It is important to note that treatment of patients with IL-7 is well tolerated even at high doses, compared to IL-2 or IL-12, making this a clinically relevant strategy. Whereas this model is designed to improve neuroblastoma T cell therapy, this strategy could be applied to T cells targeted to B-cell malignancies.
Di Stasi et al 54 demonstrated that Reed-Stemberg cells of Hodgkin lymphoma produce CCL17 and CCL2, which results in the recruitment of helper T cell 2 and Treg cells. T cells were modified to express a CD30-specific CAR and CCR4 to increase recruitment to the Reed Stemberg cells. Using an immunocompromised murine model, expression of both the CD30-targeted CAR and CCR4 resulted in increased in vivo migration and antitumor efficacy with an overall cure rate of 57% in treated mice. Similar studies have been described modifying T cells with CXCR2. 55 This study demonstrates that trafficking of T cells can be manipulated to ensure tumor localization and on-target effects.
Constitutive expression of costimulatory ligands has also been proposed to improve the antitumor function of CAR T cells.
Stephan et al 56 modified T cells to express a prostate-specific membrane antigen-targeted CAR and CD80 and 4-1BB ligand (41BBL). These cells have robust proliferative responses to stimulation in vitro and in vivo, and mediated rejection of established systemic tumor in an immunodeficient preclinical murine model. Furthermore, the CAR/CD80/41BBL T cells mediated bystander activation of tumor-specific bystander cells, indicating the potential of these cells to further recruit effective antitumor responses from TIL.
COMBINATION TREATMENTS AND OTHER APPROACHES
Combining CAR T cells with other agents may increase the antitumor efficacy of adoptive therapy. Here, we discuss a few strategies to further activate the T cells, dampen the inhibitory microenvironment, or sensitize the tumor to the T cells.
The hostile tumor microenvironment includes the upregulation of ligands that bind inhibitory receptors on T cells. Programmed death receptor 1 (PD-1) is expressed on activated T cells, and interaction with its ligands, PD-L1 or L2, can induce anergy or apoptosis in the T cells. John et al 57 modified T cells with a Her2-specific CAR and demonstrated that culture of targeted T cells with PD-L1 + tumors led to increased PD-1 expression on the T cell. Monoclonal antibodies were used to block PD-1 from interacting with PD-L1 resulting in increased IFN-γ, proliferation marker Ki67, and GzmB in CAR T cells. This combined therapy had increased in vivo antitumor efficacy using 2 orthotopic murine tumor models. Whereas this model does not investigate B-cell malignancies, it is well documented that B-cell lymphomas can express PD-L1; therefore, this approach could improve CD19-targeted T cell therapy.
Monoclonal antibody therapy has also been combined with dual-specific CAR T cells. Second-generation CARs specific for CD19 or CD38 were used for treating non-Hodgkin lymphoma. 58 The authors noted an additive effect of using 2 CARs, although complete eradication of tumor was only observed when the mice were also treated with rituximab. This combination has a high potential for clinical translation given that both CAR therapy and rituximab therapy are currently individually used in the clinic.
Small molecule inhibitors may sensitize tumors to T cellmediated destruction; therefore, combination therapy of CAR T cells and existing drugs may improve overall antitumor efficacy. Small-molecule histone deacetylase inhibitors can restore the apoptotic pathway in tumor cells and are currently being tested clinically. Karlsson et al 59 investigated the combination of CD19-specific CAR T cells with Bcl-2 family inhibitor, ABT-737. ABT737 blocks apoptosis inhibitors that are often overexpressed in tumor cells, and as a single agent has shown efficacy against CLL and B-ALL. Combination ABT 737/CAR T cell treatment had a synergistic effect on apoptosis induction in tumor cells. Furthermore, pretreatment with ABT737 improved the antitumor efficacy of CAR T cells. AKT/mammalian target of rapamycin (mTOR) pathway is often dysregulated in lymphomas and promotes tumor growth by contributing to proliferation and angiogenesis. Small molecule inhibitors like rapamycin can be used to destabilize tumors by decreasing expression of antiapoptotic molecules and down-regulating inhibitory cytokines and ligands. Huye et al 60 investigated the strategy of making tumorspecific T cells resistant to rapamycin by transducing them with both a CAR and mutated mTOR that was resistant to rapamycin (mTorRR). In the presence of rapamycin, cells expressing both the CAR and mTorRR had increased antitumor function (cytotoxicity and IFN-γ secretion) compared to cells expressing only the CAR. Chimeric antigen receptor CAR/mTorRR T cell lysed rapamycin pretreated Burkitt lymphoma Raji cells at a higher rate than untreated Raji tumor cells. Whereas these strategies require some optimization, it highlights the notion of combining smallmolecule drugs with adoptive T cell therapy.
CONCLUSION
Chimeric antigen receptor T cell therapy has recently demonstrated very promising clinical activity in B-cell hematologic malignancies. However, limitations to CAR T cell therapy exist. Relapses do occur in patients with ALL after CAR T cell therapy, and second-generation CAR T cells remain relatively ineffective in eradicating bulky lymph nodes in patients with B-cell lymphoma/leukemia. As discussed in this review, several approaches are being explored to generate armored CAR T cells to overcome the hostile tumor microenvironment and further enhance clinical activity of adoptive T cell therapy. It remains to be seen which of these approaches would be most effective and safe in the clinical setting, and well-designed clinical trials and close collaboration between the institutions will be needed to bring these next generation CARs to the clinic successfully.
